CytomX Therapeutics (STU:6C1) 5-Year EBITDA Growth Rate : 42.40% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is CytomX Therapeutics 5-Year EBITDA Growth Rate?

CytomX Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was €0.14.

During the past 3 years, the average EBITDA Per Share Growth Rate was 67.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 42.40% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 7.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of CytomX Therapeutics was 67.50% per year. The lowest was -57.10% per year. And the median was -4.85% per year.

Competitive Comparison of CytomX Therapeutics's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, CytomX Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytomX Therapeutics's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's 5-Year EBITDA Growth Rate falls into.

CytomX Therapeutics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

CytomX Therapeutics (STU:6C1) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

CytomX Therapeutics 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

CytomX Therapeutics (STU:6C1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (STU:6C1) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

CTMX:USA 6C1:Germany

Address

151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.cytomx.com

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics (STU:6C1) Headlines

No Headlines